An interventional study of Assessment of executive functions and attention and Evaluation on a driving simulator in Autism Spectrum Disorders, sponsored by Hopital La Musse. Recruiting at 1 site in France. Open to participants aged 15 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Hopital La Musse · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Autism Spectrum Disorder with a site in France — 51 open to participants now, 55 under way, 2 of them phase 3. Autism Spectrum Disorder · France.
Among the 110 studies in Autism Spectrum Disorder with a site in France, this one is the 64th largest by planned enrollment of the 77 interventional ones that give a count, is one of 15 that started in 2026, is one of 58 with no phase, reaches primary completion later than 28 of the 54 other live ones, and was the 106th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →51 of the 110 studies in Autism Spectrum Disorder with a site in France are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in France, United States, Germany and 7 more countries
Ages 5–17
Hospices Civils de Lyon · Sites in France
Ages 5–50
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 8–16
Universite Cote d'Azur · Sites in France
Ages 3–22 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 15 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 9
First in 2007; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 22 is below the median of 52 across 1,374 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 70 across the 77 interventional studies, 120 across the 33 observational. Of the 43 that completed or were terminated, 8 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 110 have an industry lead sponsor. The 10 most frequent:
Hopital La Musse is the lead sponsor of 14 studies on the registry; 5 are open to participants now.
Hopital La Musse has 2 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
17 of the studies in Autism Spectrum Disorder with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07655115Phase 3Hospital General Universitario Gregorio MarañonSingle Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th | 2026-12-31 |
| NCT06871696Institut National de la Santé Et de la Recherche Médicale, FranceGenetic of Intellectual Deficiency and Autism Spectrum Disorders (RaDiCo-GenIDA) | 2026-11 |
| NCT05512637University Hospital, MontpellierScreening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers | 2026-11 |
| NCT04638452Centre Hospitalier Charles Perrens, BordeauxEvaluation of Behavioural Psycho & Physiological Responses in People With ASD During a Blood Test in Routine Care Practice | 2026-11-30 |
| NCT05864508University Hospital, ToulouseInterest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disorders and Moderate to Severe Intellectual Disability: Feasibility and Safety Study. | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 110 studies in Autism Spectrum Disorder with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare the number of driving errors made by novice adolescents (0-5 hours of driving instruction) with ASD to those made by neurotypical adolescents during a standardized driving simulator assessment. The secondary objectives of the study are to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ASD Group
Neurotypical group:
Exclusion Criteria:
Once enrolled, each participant will undergo an assessment of executive functions and attention (conducted by a neuropsychologist, lasting 1 hour and 30 minutes) using the following tests: * Attention Assessment Test (TAP), * Trail Making Test (TMT), which assesses mental flexibility, * Stroop Selective Attention Test, assessing the ability to inhibit automatic processes, * Wisconsin Card Sorting Test (WSCT-modified), assessing abstract reasoning and the ability to change cognitive strategies in response to changes in the environment. Each adolescent will then undergo two driving assessments: one on a driving simulator and one on the road in a dual-control vehicle with a driving instructor.
Other: Assessment of executive functions and attention · Other: Evaluation on a driving simulator · Other: Evaluation on-road
Once enrolled, each participant will undergo an assessment of executive functions and attention (conducted by a neuropsychologist, lasting 1 hour and 30 minutes) using the following tests: * Attention Assessment Test (TAP) (25), * Trail Making Test (TMT), which assesses mental flexibility (26), * Stroop Selective Attention Test, assessing the ability to inhibit automatic processes (27), * Wisconsin Card Sorting Test (WSCT-modified), assessing abstract reasoning and the ability to change cognitive strategies in response to changes in the environment (28). Each adolescent will then undergo two driving assessments: one on a driving simulator and one on the road in a dual-control vehicle with a driving instructor.
Other: Assessment of executive functions and attention · Other: Evaluation on a driving simulator · Other: Evaluation on-road
* Attention Assessment Test (TAP), * Trail Making Test (TMT), which assesses mental flexibility, * Stroop Selective Attention Test, assessing the ability to inhibit automatic processes, * Wisconsin Card Sorting Test (WSCT-modified), assessing abstract reasoning and the ability to change cognitive strategies in response to changes in the environment.
The 1-hour simulator assessment will be preceded by a 1.5-hour orientation session. The simulator used is the Rehab Evolution, manufactured by Develter Innovation.
The on-road evaluation will be conducted using a dual-control vehicle, with a certified driving instructor and an occupational therapist. The evaluation will last one hour.
Assessment of driving errors in various scenarios using a driving simulator.
Each adolescent's driving performance will be measured, following Michon's model, through two distinct levels of assessment: * Assessment 1 focuses more on the operational level of Michon's model: the participant must control their vehicle while stationary and on the road under simple conditions, i.e., with no other road users and no incidents. During 5 tests, control of the controls, maintaining a straight line and staying in the lane when turning, and maintaining speed at low speeds (50 km/h) and moderate speeds (80 km/h) will be evaluated. * Assessment 2, which places greater emphasis on tactical skills: The participant will be confronted with more complex situations requiring adaptation of driving to road conditions and other road users. The aim is to gradually introduce additional cognitive demands: visual attention, visual scanning, interaction with other road users, and the management of critical situations in urban and rural environments through six tests.
Time frame: At enrollment
Visual exploration
Visual exploration will be assessed during simulator driving using an infrared eye-tracking device, the Tobii Pro Spark. This device, paired and synchronized with Develter Innovation's Rehab Evolution driving simulator, will collect eye-tracking data (e.g., number of fixations, fixation duration) from each subject during each scenario at a frequency of 60 Hz.
Time frame: At enrollment
Driving performance on the simulator
Driving performance on the simulator will be evaluated, on the one hand, using data on speed, reaction time, following distance, and braking distance collected during each test. Additionally, the total driving error score will be broken down into 7 sub-scores, allowing for the evaluation and comparison of driving error types and the levels involved in relation to Michon's model: * Control of vehicle controls, * Lane keeping and speed regulation, * Vehicle control during turns and speed regulation, * Visual scanning and divided attention while driving, level 1, * Visual scanning and divided attention while driving, level 2, * Executive functions level 1: interactions with traffic, * Executive functions level 2: management of critical situations. This scale was developed specifically for the study. Scores on the scale range from 0 to 100; the lower the score, the better the teenager's driving performance on the simulator.
Time frame: At enrollment
Driving performance on-road
During the on-road evaluation, the TRIP scale (Test Ride for Investigating Practical fitness to drive) will be used and completed immediately after the test by an occupational therapist. This test allows for the standardization and quantification of driving performance using a list of behavioral items: lane position, following distance, speed, visual scanning, traffic signals, passing, anticipation, communication, special situations, vehicle controls, and overall impressions. Each item is quantified using a score on a scale of 1 to 4 (1: insufficient, 2: questionable, 3: sufficient, 4: good). The reliability of this test has already been demonstrated in several studies involving various populations, such as older adults, stroke survivors, and individuals with Huntington's disease. This grid also allows for the calculation of scores corresponding to the different hierarchical levels of Michon's model.
Time frame: At enrollment
Anxiety - State-Trait Anxiety Inventory Y-form
Participants' anxiety levels during on-road and simulator driving tests will be assessed using the STAI-Y (State-Trait Anxiety Inventory Y-form). It will be administered and completed before and after each assessment, both on-road and in the simulator. The general STAI-Y is a questionnaire designed to assess momentary anxiety and trait anxiety. For this study, only the state scale of the STAI-Y will be used. The state anxiety scale comprises 20 items and assesses the feelings of apprehension, tension, nervousness, and worry that the subject experiences at the time of the assessment. The STAI-Y scale ranges from 20 to 80. The higher the score, the greater the level of anxiety.
Time frame: At enrollment
Assessment of executive functions and attention
Assessment of executive functions and attention using the Attention Assessment Test (TAP) with the following subtests: "phasic alerting," "divided attention," "go/no go," "working memory," and "visual scanning", the Trail Making Test (TMT) assessing mental flexibility, the Stroop selective attention test assessing the ability to inhibit automatic processes, and the Wisconsin Card Sorting Test (WSCT-modified), which assesses abstract reasoning and the ability to change cognitive strategies in response to changes in the environment.
Time frame: At enrollment
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.
Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 8 months is below that.
Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hopital La Musse